Skip to main content
Erschienen in: Annals of Nuclear Medicine 2/2017

03.11.2016 | Original Article

Generating harmonized SUV within the EANM EARL accreditation program: software approach versus EARL-compliant reconstruction

verfasst von: Charline Lasnon, Thibault Salomon, Cédric Desmonts, Pascal Dô, Youssef Oulkhouir, Jeannick Madelaine, Nicolas Aide

Erschienen in: Annals of Nuclear Medicine | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Evolutions in hardware and software PET technology, such as point spread function (PSF) reconstruction, have been shown to improve diagnostic performance, but can also lead to important device-dependent and reconstruction-dependent variations in standardized uptake values (SUVs). This may preclude the multicentre use of SUVs as a prognostic or diagnostic tool or as a biomarker of the early response to antineoplastic treatments. This study compared two SUV harmonization strategies using a newer reconstruction algorithm that improves lesion detection while maintaining comparability with older systems: (1) the use of a second reconstruction compliant with harmonization standards and (2) the use of a proprietary software tool (EQ.PET).

Methods

PET data from 50 consecutive non-small cell lung cancer patients were reconstructed with PSF reconstruction for optimal tumor detection and an ordered subset expectation maximization (OSEM3D) reconstruction to mimic a former generation PET. An additional PSF reconstruction was performed with a 7 mm Gaussian filter (PSF7, first method), and, post-reconstruction, the EQ filter (same Gaussian filter) was applied to the PSF data (PSFEQ, second method) for harmonization purposes. The 7 mm kernel filter was chosen to comply with the European Association of Nuclear Medicine (EANM) standards. SUVs for all reconstructions were compared with regression analyses and/or Bland–Altman plots.

Results

Overall, 171 lesions were analyzed: 55 lung lesions (32.2%), 87 lymph nodes (50.9%), and 29 metastases (16.9%). In these lesions, the mean PSF7/OSEM3D ratios for SUVmax and SUVpeak were 1.02 (95% CI: 0.93–1.11) and 1.04 (95% CI: 0.95–1.14), respectively. The mean PSFEQ/OSEM3D ratios for SUVmax and SUVpeak were 1.01 (95% CI: 0.91–1.11) and 1.04 (95% CI: 0.94–1.14), respectively. When comparing PSF7 and PSFEQ, Bland–Altman analysis showed that the mean PSF7/PSFEQ ratios for SUVmax and SUVpeak were 1.01 (95% CI: 0.96–1.06) and 1.01 (95% CI: 0.97–1.04), respectively.

Conclusion

The issue of reconstruction dependency in SUV values that hampers the comparison of data between different PET systems can be overcome using two reconstructions for harmonized quantification and optimal diagnosis or using the EQ.PET technology. Both technologies produce similar results, EQ.PET sparing reconstruction and interpretation time. Other manufacturers are encouraged to either emulate this solution or to produce a vendor-neutral approach.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Bengtsson T, Hicks RJ, Peterson A, Port RE. 18F-FDG PET as a surrogate biomarker in non-small cell lung cancer treated with erlotinib: newly identified lesions are more informative than standardized uptake value. J Nucl Med. 2012;53:530–7. doi:10.2967/jnumed.111.092544.CrossRefPubMed Bengtsson T, Hicks RJ, Peterson A, Port RE. 18F-FDG PET as a surrogate biomarker in non-small cell lung cancer treated with erlotinib: newly identified lesions are more informative than standardized uptake value. J Nucl Med. 2012;53:530–7. doi:10.​2967/​jnumed.​111.​092544.CrossRefPubMed
2.
Zurück zum Zitat Konings R, van Gool MH, Bard MP, Zwijnenburg A, Titulaer BM, Aukema TS, et al. Prognostic value of pre-operative glucose-corrected maximum standardized uptake value in patients with non-small cell lung cancer after complete surgical resection and 5-year follow-up. Ann Nucl Med. 2016;30:362–8. doi:10.1007/s12149-016-1070-2.CrossRefPubMed Konings R, van Gool MH, Bard MP, Zwijnenburg A, Titulaer BM, Aukema TS, et al. Prognostic value of pre-operative glucose-corrected maximum standardized uptake value in patients with non-small cell lung cancer after complete surgical resection and 5-year follow-up. Ann Nucl Med. 2016;30:362–8. doi:10.​1007/​s12149-016-1070-2.CrossRefPubMed
3.
Zurück zum Zitat Kremer R, Peysakhovich Y, Dan LF, Guralnik L, Kagna O, Nir RR, et al. FDG PET/CT for assessing the resectability of NSCLC patients with N2 disease after neoadjuvant therapy. Ann Nucl Med. 2016;30:114–21. doi:10.1007/s12149-015-1038-7.CrossRefPubMed Kremer R, Peysakhovich Y, Dan LF, Guralnik L, Kagna O, Nir RR, et al. FDG PET/CT for assessing the resectability of NSCLC patients with N2 disease after neoadjuvant therapy. Ann Nucl Med. 2016;30:114–21. doi:10.​1007/​s12149-015-1038-7.CrossRefPubMed
4.
Zurück zum Zitat Shigemoto Y, Suga K, Matsunaga N. F-18-FDG-avid lymph node metastasis along preferential lymphatic drainage pathways from the tumor-bearing lung lobe on F-18-FDG PET/CT in patients with non-small-cell lung cancer. Ann Nucl Med. 2016;30:287–97. doi:10.1007/s12149-016-1063-1.CrossRefPubMed Shigemoto Y, Suga K, Matsunaga N. F-18-FDG-avid lymph node metastasis along preferential lymphatic drainage pathways from the tumor-bearing lung lobe on F-18-FDG PET/CT in patients with non-small-cell lung cancer. Ann Nucl Med. 2016;30:287–97. doi:10.​1007/​s12149-016-1063-1.CrossRefPubMed
5.
Zurück zum Zitat Yamamoto T, Kadoya N, Shirata Y, Kaneta T, Koto M, Umezawa R, et al. Formula corrected maximal standardized uptake value in FDG-PET for partial volume effect and motion artifact is not a prognostic factor in stage I non-small cell lung cancer treated with stereotactic body radiotherapy. Ann Nucl Med. 2015;29:666–73. doi:10.1007/s12149-015-0991-5.CrossRefPubMed Yamamoto T, Kadoya N, Shirata Y, Kaneta T, Koto M, Umezawa R, et al. Formula corrected maximal standardized uptake value in FDG-PET for partial volume effect and motion artifact is not a prognostic factor in stage I non-small cell lung cancer treated with stereotactic body radiotherapy. Ann Nucl Med. 2015;29:666–73. doi:10.​1007/​s12149-015-0991-5.CrossRefPubMed
7.
Zurück zum Zitat Panin VY, Kehren F, Michel C, Casey M. Fully 3-D PET reconstruction with system matrix derived from point source measurements. IEEE Trans Med Imaging. 2006;25:907–21.CrossRefPubMed Panin VY, Kehren F, Michel C, Casey M. Fully 3-D PET reconstruction with system matrix derived from point source measurements. IEEE Trans Med Imaging. 2006;25:907–21.CrossRefPubMed
9.
Zurück zum Zitat Tong S, Alessio AM, Kinahan PE. Evaluation of noise properties in PSF-based PET image reconstruction. IEEE Nucl Sci Symp Conf Rec. 1997;2009(2009):3042–7. Tong S, Alessio AM, Kinahan PE. Evaluation of noise properties in PSF-based PET image reconstruction. IEEE Nucl Sci Symp Conf Rec. 1997;2009(2009):3042–7.
11.
Zurück zum Zitat Bellevre D, Blanc Fournier C, Switsers O, Dugue AE, Levy C, Allouache D, et al. Staging the axilla in breast cancer patients with (1)(8)F-FDG PET: how small are the metastases that we can detect with new generation clinical PET systems? Eur J Nucl Med Mol Imaging. 2014;41:1103–12. doi:10.1007/s00259-014-2689-7.CrossRefPubMedPubMedCentral Bellevre D, Blanc Fournier C, Switsers O, Dugue AE, Levy C, Allouache D, et al. Staging the axilla in breast cancer patients with (1)(8)F-FDG PET: how small are the metastases that we can detect with new generation clinical PET systems? Eur J Nucl Med Mol Imaging. 2014;41:1103–12. doi:10.​1007/​s00259-014-2689-7.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Lasnon C, Hicks RJ, Beauregard JM, Milner A, Paciencia M, Guizard AV, et al. Impact of point spread function reconstruction on thoracic lymph node staging with 18F-FDG PET/CT in non-small cell lung cancer. Clin Nucl Med. 2012;37:971–6. doi:10.1097/RLU.0b013e318251e3d1.CrossRefPubMed Lasnon C, Hicks RJ, Beauregard JM, Milner A, Paciencia M, Guizard AV, et al. Impact of point spread function reconstruction on thoracic lymph node staging with 18F-FDG PET/CT in non-small cell lung cancer. Clin Nucl Med. 2012;37:971–6. doi:10.​1097/​RLU.​0b013e318251e3d1​.CrossRefPubMed
13.
Zurück zum Zitat Rogasch JM, Steffen IG, Hofheinz F, Grosser OS, Furth C, Mohnike K, et al. The association of tumor-to-background ratios and SUVmax deviations related to point spread function and time-of-flight F18-FDG-PET/CT reconstruction in colorectal liver metastases. EJNMMI Res. 2015;5:31. doi:10.1186/s13550-015-0111-5.CrossRefPubMedPubMedCentral Rogasch JM, Steffen IG, Hofheinz F, Grosser OS, Furth C, Mohnike K, et al. The association of tumor-to-background ratios and SUVmax deviations related to point spread function and time-of-flight F18-FDG-PET/CT reconstruction in colorectal liver metastases. EJNMMI Res. 2015;5:31. doi:10.​1186/​s13550-015-0111-5.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Parvizi N, Franklin JM, McGowan DR, Teoh EJ, Bradley KM, Gleeson FV. Does a novel penalized likelihood reconstruction of 18F-FDG PET-CT improve signal-to-background in colorectal liver metastases? Eur J Radiol. 2015;. doi:10.1016/j.ejrad.2015.06.025.PubMed Parvizi N, Franklin JM, McGowan DR, Teoh EJ, Bradley KM, Gleeson FV. Does a novel penalized likelihood reconstruction of 18F-FDG PET-CT improve signal-to-background in colorectal liver metastases? Eur J Radiol. 2015;. doi:10.​1016/​j.​ejrad.​2015.​06.​025.PubMed
17.
18.
Zurück zum Zitat Boellaard R, O’Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37:181–200. doi:10.1007/s00259-009-1297-4.CrossRefPubMed Boellaard R, O’Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37:181–200. doi:10.​1007/​s00259-009-1297-4.CrossRefPubMed
21.
Zurück zum Zitat Lasnon C, Desmonts C, Quak E, Gervais R, Do P, Dubos-Arvis C, et al. Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients. Eur J Nucl Med Mol Imaging. 2013;40:985–96. doi:10.1007/s00259-013-2391-1.CrossRefPubMedPubMedCentral Lasnon C, Desmonts C, Quak E, Gervais R, Do P, Dubos-Arvis C, et al. Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients. Eur J Nucl Med Mol Imaging. 2013;40:985–96. doi:10.​1007/​s00259-013-2391-1.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Quak E, Le Roux PY, Hofman MS, Robin P, Bourhis D, Callahan J, et al. Harmonizing FDG PET quantification while maintaining optimal lesion detection: prospective multicentre validation in 517 oncology patients. Eur J Nucl Med Mol Imaging. 2015;42:2072. doi:10.1007/s00259-015-3128-0.CrossRefPubMedPubMedCentral Quak E, Le Roux PY, Hofman MS, Robin P, Bourhis D, Callahan J, et al. Harmonizing FDG PET quantification while maintaining optimal lesion detection: prospective multicentre validation in 517 oncology patients. Eur J Nucl Med Mol Imaging. 2015;42:2072. doi:10.​1007/​s00259-015-3128-0.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Sunderland JJ, Christian PE. Quantitative PET/CT scanner performance characterization based upon the society of nuclear medicine and molecular imaging clinical trials network oncology clinical simulator phantom. J Nucl Med. 2015;56:145–52. doi:10.2967/jnumed.114.148056.CrossRefPubMed Sunderland JJ, Christian PE. Quantitative PET/CT scanner performance characterization based upon the society of nuclear medicine and molecular imaging clinical trials network oncology clinical simulator phantom. J Nucl Med. 2015;56:145–52. doi:10.​2967/​jnumed.​114.​148056.CrossRefPubMed
28.
Zurück zum Zitat Kuhnert G, Boellaard R, Sterzer S, Kahraman D, Scheffler M, Wolf J, et al. Impact of PET/CT image reconstruction methods and liver uptake normalization strategies on quantitative image analysis. Eur J Nucl Med Mol Imaging. 2015;. doi:10.1007/s00259-015-3165-8. Kuhnert G, Boellaard R, Sterzer S, Kahraman D, Scheffler M, Wolf J, et al. Impact of PET/CT image reconstruction methods and liver uptake normalization strategies on quantitative image analysis. Eur J Nucl Med Mol Imaging. 2015;. doi:10.​1007/​s00259-015-3165-8.
30.
Zurück zum Zitat Hasenclever D, Kurch L, Mauz-Korholz C, Elsner A, Georgi T, Wallace H, et al. qPET - a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:1301–8. doi:10.1007/s00259-014-2715-9.CrossRefPubMed Hasenclever D, Kurch L, Mauz-Korholz C, Elsner A, Georgi T, Wallace H, et al. qPET - a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:1301–8. doi:10.​1007/​s00259-014-2715-9.CrossRefPubMed
Metadaten
Titel
Generating harmonized SUV within the EANM EARL accreditation program: software approach versus EARL-compliant reconstruction
verfasst von
Charline Lasnon
Thibault Salomon
Cédric Desmonts
Pascal Dô
Youssef Oulkhouir
Jeannick Madelaine
Nicolas Aide
Publikationsdatum
03.11.2016
Verlag
Springer Japan
Erschienen in
Annals of Nuclear Medicine / Ausgabe 2/2017
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-016-1135-2

Weitere Artikel der Ausgabe 2/2017

Annals of Nuclear Medicine 2/2017 Zur Ausgabe

Acknowledgements to Reviewers

Acknowledgements to reviewers